Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures
Asian Markets Mixed as RBI Cuts Rates and BOJ Signals Possible Hike
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 



